#### **SUMMARY**

When too much uric acid enters the joints of an arthritis patient, gout develops. Chronic refractory gout is treated with immunosuppressive drugs. Unfortunately, 92% of patients treated develop an immunogenic reaction to the drugs and discontinue treatment. As a result, the efficacy of current treatment is limited.

Selecta Biosciences designed SEL-212 as a combination of pegylated uricase and rapamycin, an immunosuppressive drug. However, Selecta added ImmTOR to rapamycin to overcome the immunogenic reactions of gout patients. ImmTOR (immune tolerance) is a biodegradable, nanoparticle, encapsulating technology. SEL-212 demonstrated in clinical studies it mitigates the formation of anti-drug antibodies, which prevent patients from continuing treatment.

After a phase II dose selection trial, Selecta decided to test SEL-212 in a head-to-head phase II trial against KRYSTEXXA (pegloticase), a leading immunosuppressive drug marketed by Horizon Therapeutics (NASDAQ:HZPN). SanaCurrents assigns an advantageous sentiment that SEL-212 will be superior to pegloticase in the comparison trial.

Reducing serum uric acid (SUA) is the key marker in managing the onset of severe gout, which can last between 7 and 14 days. Selecta designed the phase II comparison trial with the primary endpoint of superiority for an SUA level less than 6 mg/dl after six months. Other secondary endpoints include frequency of flares and quality of life.

In a previous, dose-selection phase II trial of 152 patients, Selecta reported 66% (21 out of 32) of patients in three cohorts of the trial experienced a **reduction in SUA** of less than 6 mg/dl after five months. The three cohorts were the only groups among the 152 patients to receive both pegylated uricase and ImmTOR-formulated rapamycin continuously during the entire trial.

Overall, there was a 9-fold reduction in the number of flares patients experienced in the five months of the trial. Only 4% of the flares were considered serious, while 64% were mild and 32% were moderate.

Chronic refractory gout afflicts 160,000 people annually in the US. Selecta estimates the market size at more than \$1 billion. KRYSTEXXA (pegloticase) recorded approximately \$260 million in sales in 2018.

#### THE EDGE

Selecta's ImmTOR technology can be applied broadly in other biologics and gene therapy drugs. In fact, the company has gene therapy programs in its pipeline for Hemophilia A and Pompe disease. Yet it chose SEL-212 as its lead program for ImmTOR.

In deciding to test SEL-212 in a serious but not necessarily life-threatening indication, Selecta chose a good target to demonstrate how ImmTOR can tamp down the immune system response. The data from the dose-selecting phase II trial appears strong enough to improve upon existing immunosuppressive

# PROBABILITY SENTIMENT SUPERIOR (highest) Pivotal Advantageous

#### **Key Catalyst(s)**

 Topline data from SEL-212 comparison trial in chronic refractory gout

#### **Key Catalyst Date(s)**

mid-2020

#### **Insider & Institutional Holdings**

31.50% % of Shares Held by All Insider

92.28% % of Shares Held by Institutions

134.71%% of Float Held by Institutions

**50** Number of Institutions Holding Shares

#### **Key Executives**

Dr. Carsten Brunn, CEO, Pres & Director

Mr. Stephen Smolinski, Chief Commercial Officer

**Dr. Ulrich H. von Andrian-Werburg,** Co-Founder and Co-Chair of the Scientific Advisory Board

**Mr. Bradford D. Dahms**, CFO, Principal Financial Officer & Principal Accounting Officer

**Dr. Lloyd Johnston**, COO and Sr. VP of R&D

#### Location

480 Arsenal Way Watertown, MA 02472 United States 617-923-1400

#### http://selectabio.com

#### General Guidelines for SanaCurrents Strategy

Based on SanaCurrents' analytical model, Superior and Pivotal sentiments reflect a probability score of at least 60% that the company will announce a positive result to the specified catalyst. In our experience, a positive result typically increases the company's share price. An Advantageous sentiment reflects a score of less than 60%. See more on SanaCurrents' actions on page

# Selecta Biosciences (NASDAQ:SELB)

#### THE EDGE cont'd

treatments, such as pegloticase.


More important, pegloticase and other immunosuppressive drugs are inducing patient reactions to the drugs. SEL-212 has demonstrated a low incidence of anti-drug antibodies (ADAs) as well as SUA reduction in the previous phase II trial. The low incidence of ADAs likely tipped Selecta toward deciding on a head-to-head trial with pegloticase. Not only should SEL-212 demonstrate a reduction in SUA, it likely will establish a lower ADA level than pegloticase. The two improvements should impress clinicians and regulators, and move SEL-212 faster to the market.

KRYSTEXXA (pegloticase) also has a checkered past in the market. The drug was developed originally by Savient Pharmaceuticals, which went bankrupt after attempting to sell the drug for \$14,000 per year. A private equity company bought Savient, repositioned the drug and sold it to Horizon in 2015 for \$510 million.

The annual price of KRYSTEXXA (pegloticase) ranges between \$3,000 and \$5,000 per year. Even though the drug is not exclusively used for gout, the price is steep for a drug that induces immunogenic reactions and subsequent complications in treatment. An option such as SEL-212 will win over payers, clinicians and regulators, provided SEL-212 repeats the superiority to pegloticase it exhibited in previous studies

#### General Guidelines for SanaCurrents Strategy cont'd

In most situations, SanaCurrents partners take a position in a stock (or buy shares) shortly after a report on a catalyst is published. This is particularly true if the catalyst is within 90 days of the published report. For catalysts with horizons of 6-9 months, or longer, SanaCurrents anticipates the biopharma and device stocks from which it selects catalysts can rise or fall 20-30% in the months following the date of the published report. While buying at a dip, naturally, is preferred, SanaCurrents does not forecast or model in swings in share price prior to the catalyst. SanaCurrents' analytics score models the probability a compelling catalyst will be positive. SanaCurrents expects a positive announcement regarding a catalyst will drive a company's stock to higher level than the price on the date of the report, based on the company's value and capital structure when the report was published. That said, subscribers should exercise their preferred, individual discipline when timing trades, buy or sell, regarding the catalyst forecast.



# Selecta Biosciences (NASDAQ:SELB)

### **Advanced Tear Sheet**

Selecta Biosciences	TING			USD	4.22	0.05	17%					
Country	United States of America				Next FQF	H End Date	Dec 21, 2019					
Exchange	NASTIACI Stock Market				Next F	Y End Date	Disc 21, 2019					
GICS Sector	Heath Care				Next ex	rnings Date	(Mw 15, 2000)	.0				
GICS Industry	Bosedvickopy				Latest ea	rnings Date	New 05, 2019	1/				
Currency	USD					A005 A000		0	Sel	act	7	
General Information					*Jer cost	ione 5/50, excep	t per obove data	7	201	CCI	J111	
Price (Previous Close)	1432			10.0	Div. Yield, Last	year (FYD)		0	Bios	CIC	no	00
Price - 52 Work High	480				Shares Outstar	niing	22 E MAR.		DIO	SCIC		
Price - Current vs 52wk High	1262%				Short Interest S	ihares	DAMM					
Price - 12 Week Lew	130				SI % of 0.%		2.00%					
Price - Current vs 52wk Low	200 00%			11	Market Capital	zation	200					
Bote - Sampling last by, Daily	C95 v	s S&P 500			Not Diebt		760					
					Enterprise Val	ne.	190					2.276
Estimates revision momentu	ett (					"In millione b	SD, encept EPS	Per Share Metrics	FY.2	FY-1	FYB	*in Lt
	Last reported FY		Corrent Year F	PY1		Mest Year F	Y2	Book Value:	2.90	232	0.24	-0
		Broth ago	Seeth ago:	Today	firstly age:	Droth ago	Today	Free Cash Flow:	-1.10	230	400	
Consensus delle		8.22/2019	11/22/2019	2/22/2020	8.22/2019	11/22/2019	2/22/2020	Dividend:	0.00			10
Revenue	- 1	0.	1	0	10	- 11	1	Earnings (EPS):	-3.00	330	10	- 1
% shift to today		×10.7%	0.0%		100,0%	100.00		THE STATE OF THE S	contai	00000		100
Gross Profit	1	0	1	0				Valuation ratios				
% ahlf to today		-10 (%)	00%	1	160	199		16	LTM	NTM	FYI	- 1
EBIT	46	49	-62	-63	-71	-50	-89	EWSales.	2063 v	4700.00	201 to 1	1000011
% diff to today		-10 06	-03%		-21.7%	0.0%		EVERITRA				
EBITOA	-64	40			-66			P/E				
% aff to today		Mil	100		100	199		PE to Growth (PEG)				
EPS	322	1133	11.00	-1799	-110	0.92	oni	EWFOR				
% diff to rooley		-10.3%	4.00	A CONTRACTOR	148.86	0.36		P/Sales		(98624)	10100.4 (	2011900
								P/BV	472 4			
Consolidated Income Statem								P/Tangikie BV	879 v			
	AND			Name and Address of Party	Townson White	1605 (v41 med	Constitution in England	P/Tangane Dy				
	nent FY &	FY4	FY3	in milione USI FY 2	), except dilute FY-8	FY0	Syn-CAGR	Consolidated Balance			*in	multicina Lit
Period and rights	WHAT IN THE PARTY OF THE PARTY	FY4				-		0.000		FY-2	*M	
	WHAT IN THE PARTY OF THE PARTY	FY4	FY3	FY-2	FY-t	FYO		0.000		FY-2 12/31/2016		F
Pariod and rights	WHAT IN THE PARTY OF THE PARTY		FY3	FY 2 12/31/2016	EY-1 12/31/2017	FYO	Syn-CAGR	Consolidated Balance			FY.1	F
Period and cable Sales	WHAT IN THE PARTY OF THE PARTY	- 1	FY-3 12/31/2015	FY-2 12/31/2016	EY-8 12/31/2017	FYO	Syn-CACR	Consolidated Balance		12/31/2016	FY-1 12/31/2017	F
Period sed option Sales Gross Income	WHAT IN THE PARTY OF THE PARTY	3 3	FY3 12/31/2015	FY-2 12/31/2016	EY-1 12/91/2017	FY0 12/91/2818	Syr-CAGR	Consolidated Balance : Percol end date Cash & ST Investments		12/31/2016	FY-1 12/31/2017	12/31/26
Period and calls Sales Gross Income EBITDA (adj.)	WHAT IN THE PARTY OF THE PARTY	1	FY3 12/31/2015 6 6 24	FY 2 12/31/2016	FY-1 12/91/2017 0 11	FY0 12/31/2818	byr-CAGR	Consolidated Balance  Perceived date Cash & ST Investments Investory		12/31/2016	EY-1 12/31/2017	12/31/26
Period and odes Sales Gross Income EERTDA (edj.) EERT (edj.)	WHAT IN THE PARTY OF THE PARTY	- 3 - 3 - (8) - 45	FY3 12/31/2015 1 1 31 35	FY 2 12/31/2016	FY-1 12.91/2017 0 0 43 44	FY0 12/91/2018	Syr-CACR	Consolidated Balance  Percol and date Clash & ST Investments Investory Total Assets		12/31/2016	EY.1 12:01:2017	12/31/20
Percet over 1984 Sales Gross Incarne EBRTDA (edj.) EBRT (edj.) Earnings Before Tax (edj.)	WHAT IN THE PARTY OF THE PARTY	3 3 10 15	FY3 12/31/2015 1 1 31 35	FY 2 12/31/2016	FY-1 12/91/2017 0 0 0 0 0 0 0 0 0 0 0 0	FY0 12/91/2018	5yr-CAGR -04.2% -04.2% -04.2% -0.2% -0.2%	Consolidated Balance  Percol and date Clash & ST Investments Inventory Tetal Assets Current Lightins		12/31/2016 %4 89 14	FY-1 12:31:2017	12/31/20
Period and side Sales Gross Secure EESTDA (adj.) EEST (adj.) Earnings Settoro Tax (adj.) Not Income (adj.)	WHAT IN THE PARTY OF THE PARTY	3 (t) (t) (t) (t)	FY3 12/31/2015 1 1 31 35	FY2 1231-2016 II II II II II II II II II	FY-1 12/91/2017 0 0 63 44 45	FY0 12/91/2818 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	5yr-CAGR -04.2% -04.2% -04.2% -0.2% -0.0%	Consolidated Balance  Period end date Clash & ST Investments Inventory Tetal Assets Coverd Labidios Total Oebt	Sheet	12.01.0916 94 89 14 12	FY-1 12:31:2017 311 111 21	milions L <sup>2</sup> F 12/31/20
Period and side  Sales  Gross Incurre  EBRTUA (ed.)  Earnings Beldyn Tax (ed.)  Not Income (edf.)  Ditund EPS (edj.)	FV-S	3 3 46 45 43 43 457	FY3 12/91/2015 1 1 21 	FY-2 12/91-9016	FY-8 12/91/2017 0 10 63 64 65 66 66 520	FY0 12/31/2018 1 64 45 45 45	5yr-CAGR -04.7% -04.7% -0.2% -0.2% -0.2% -0.2% -0.2%	Consolidated Balance  Percol end date Clash & ST Investments Inventory Total Assets Covered Labeltos Total Oebt Total Liabilities	Sheet	12:01:2016 84 85 14 12 34	FY-1 12/31/2017 27 931 11 21 48 52	12/31/20
Percet section  Sales  Gross Incurre  EERTDA (edg)  EERT (adg)  Earnings Before Tax (adg)  Not Income (adg)  Ditand EPS (adg)  Common Shores  Margins & Prefixability Racio	FV-S	3 3 46 45 43 43 457	FY3 1231/2015 1 1 24 25 25 25	FY 2 12/31/2016	FY-8 12/91/2017 0 0 0 63 64 65 68 320 22	FY0 12/91/28/18 1 1 64 45 45 45 45 45 45 22 22	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Percolect date Clash & ST Investments Investment Total Assets Current Labilities Total Clash Total Clash Total Shareholders Equily  Consolidated Cash Flo	Sheet	12/31/2016 84 85 14 12 34 55	FY-1 12:01:0017 801 11: 21: 49: 52:	# 12/31/26
Period sect side  Sales  Gross Incurre  EESTDA (adj.)  EEST (adj.)  Earnings Before Tax (adj.)  Not Income (adj.)  Ditanet EPS (adj.)  Common Shores  Marajines & Fredrichbility Robin  Period end other	FV-S	3 3 46 45 43 43 457 6	FY3 1231/2015 1 1 2 2 2 2 2 5 2 1 1 1 1 1 1 1 1 1 1	FY 2 12/31/2016	PY-8 12/01/2017 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	FY0 12/31/2018 1 1 1 64 65 65 65 202 22 27	5yr-CACR -04.2% -04.2% -41.2% -60.2% -60.2% -10.	Consolidated Balance  Percol and date Clash & ST Investments Inventory Tetal Assets Current Liabilities Total Clash Total Liabilities Total Shareholders Equity Consolidated Cash Flor	Sheet	12/31/2016 84 85 14 12 34 55 FY-2 12/31/2016	FY-1 12/31/2017 11 11 11 11 12 12 15 17 17 17 17 17 17 17 17 17 17 17 17 17	12/31/26 12/31/26 12/31/26
Percet sees Sales Gross Income EEST (Adj.) Earnings Before Tax (Adj.) Not Income (Adj.) Dilated EPS (Adj.) Common Shares Margins & Freditability Radio Percet adde	FV-S	3 3 46 45 45 43 45 45 45 45 45 45 45 45 45 45 45 45 45	PY3 1231/2015  1 23 25 25 25 FY3 1231/2019	FY2 12/31/2016	FY-1 12/31/2017  0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0	FY0 12/31/2018 1 1 1 64 45 45 45 45 45 20 22 22 22 23	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Autor and date Cash & ST Investments Inventory Total Assets Cover Labeline Total Shareholders Equity Consolidated Cash Flo Perior and date National	Sheet	12.01/2016 14 15 14 12 34 55 FY-2 12.01/2016	FY-1 12/31/2017  881 11 21 49 52 FY-1 12/31/2017	# 12/31/26
Period and side  Sales  Gross Income  EBRTUA (ed.)  EBRT (ed.)  Earnings Bedare Tax (ed.)  Not Income (ed.)  Difund EPS (ed.)  Common Shares  Margins & Profitability Rasio  Period and side  Gross Margin  R&D % of Sales	FV-S	3 3 46 46 46 46 46 46 46 46 46 46 46 46 46	FY3 1201/2015 1 1 2 2 2 2 2 5 1 1 1201/2019 1200/6 262.2%	FY2 12312916	PY-1 12010017 0 0 0 63 44 66 68 320 22 PY-1 12010017 100106 21010198	FY0 12/31/2010 1 1 1 64 65 66 66 202 22 FY0 12/31/2010 100:0%	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Aerod and date Costs & ST Inventorial Inventory Total Assets Covert Liabilities Total Liabilities Total Liabilities Total Shareholders Equity Consolidated Cash Florence and Cash Nat Incores D&A	Sheet	12.01.0016 84 85 14 12 34 55 FY-2 12.01.2016 41	FY4 12012017 11 12	12/31/26 12/31/26 12/31/26
Percol met side  Sales  Gross Income  Gross Income  EBIT (Adj.)  Earnings Before Tax (Adj.)  Not Income (Adj.)  Dilated EPS (Adj.)  Common Shares  Margins & Profitability Radio  Percol met dile  Gross Margin  R&D % of Sales  SG&A % of Sales	FV-S	3 3 40 45 45 45 45 45 45 45 45 45 45 45 45 45	FY3 12/31/2015 1 1 23 25 25 25 1 1 12/31/2019 12/31/2019 12/31/2019 12/31/2019	FY2 1231-2916	FY-1 12/31/2917 0 0 0 0 0 0 44 45 66 68 320 22 FY-1 12/31/2917 100.0% 300.47%	FY0 12/31/2010 1 1 1 66 65 65 202 22 22 12/31/2010 10/30/6 5551.0%	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Andod and date Cash & ST Inventory Total Assets Current Liabilities Total Clebs Total Shareholders Equity  Consolidated Cash Flo  Amour and date Not become D&A Changs in WC	Sheet	12/31/2016 16 16 17 17 18 19 19 19 19 19 10 10 10 10 10 10 10 10 10 10	FY4 1231,2017 ## 11 1231,2017 ## 1201,2017 ## 1201,2017 ## 15 12017 ## 15 12017 ## 15 12017 ## 15 12017 ## 15	12/31/20 12/31/20 12/31/20
Percel met side  Sales  Gross Incurre  EBETTA (adj.)  EBETTA(a)  Earnings Bethro Tax (adj.)  Not Incorne (adj.)  Diktorie (adj.)  Common Shores  Margins & Profitability Ratio  Percel margin  Ratio of Sales  SGAA % of Sales  EBITDA Margins (adj.)	FV-S	3 (t)	FY3 12/31/2015 1 1 2 2 2 2 2 5 1 1 1 12/31/2015 112/31/2015 112/31/2015 112/31/2015 112/31/2015	FY2 1231-2916  31 34 41 41 538 61 61 62 62 1231-2916 100.00 367-56 619.00 619.00	FY-1 1201/2017 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	FY0 12/31/2018 1 1 1 1 64 65 65 65 202 22 FY0 12/31/2018 102/01 5251 0% 2017/% 2017/%	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Percol end date Clash & ST Inventional Inventiony Tetal Assets Current Liabilities Total Clots Total Shareholders Equity Consolidated Cash Flo Percol end date Nat Income D&A Change in WC Cash From Operations	Sheet	12.01.0016 84 10 14 12 34 55 FY.2 12.01.2016 41 10	FY4 1231,0017 ## 1131	12/31/20 12/31/20 12/31/20
Percel sect side  Sales  Gross incurre  EERTDA (ed.)  EERTDA (ed.)  EERTDA (ed.)  Earnings Before Tax (ed.)  Not lecome (ed.)  Ditanal EPS (ed.)  Common Shores  Margins & Free(rability Radio  Percel code  Gross Margin  R&D % of Sales  SSAA % of Sales  EBITOA Margin (ed.)  EBIT Margin (ed.)	FV-S	3 (8) (8) (8) (8) (8) (8) (8) (8) (8) (8)	FY3 12/31/2015 1 1 23 25 25 25 1 1 12/31/2019 12/31/2019 12/31/2019 12/31/2019	FY2 1231-2916  3 34 41 42 41 42 41 42 41 42 41 41 42 41 41 41 41 41 41 41 41 41 41 41 41 41	FY-1 1201-2017 0 0 0 0 44 65 68 3-20 22 FY-1 1201-2017 100-9% 2101-216 3061-26 -3061-26 -3061-26	FY0 12/31/2018 1 1 1 64 65 65 2.02 23 23 FY0 12/31/2018 1000/4 SSE 04 2017/75 2017/75 2017/75 -7/30/75	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Percol and date Clash & ST Inventory Total Assets Current Labilities Total Clote Total Liabilities Total Shareholders Equily  Consolidated Gash Flo  Percol and date Not become D&A Change in WC Cash From Operations Captal Expensitures	Sheet	12.01.0016 94 105 14 12 34 55 FY-2 12.01.2016 41 10 20 -1	FY4 1231,0017 ## 1131	12/31/26 12/31/26 mations Li 12/31/26
Percel sect side  Sales  Gross Incurre  EESTDA (adj)  EEST (adj)  Earnings Before Tax (adj)  Not Income (adj)  Dikmed EPS (adj)  Common Shores  Margines & Fredhobility Reside  Fred ond other  Gross Margin  R&D % of Sales  SG&A % of Sales  EBITDA Margin (adj)  Ret Margin (adj)  Not Margin (adj)	FV-S	1000N 34154 413 413 4157 4 4000N 34154 478154 478154 478154 478154 478154 478154 478154	FY3 12/31/2015 1 1 2 2 2 2 2 5 2 5 1 1 12/31/2015 102.05 2 12/31/2015 102.05 26.25 402.05	FY2 1231-2916  31 34 41 41 538 61 61 62 62 1231-2916 100.00 367-56 619.00 619.00	PY-1 12/01/2017  0 0 0 43 44 66 68 320 22  PY-1 12/01/2017 100/09 2016/09 3046/25 3066/25 3066/25	FY0 12/31/2018 1 1 1 1 65 65 65 2.02 22 22 FY0 12/31/2018 102/04 525 0% 2017/76 2017/76	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Annor and date Cash & ST Investments Inventory Total Assets Covert Labritos Total Labritos Total Shareholders Equity Consolidated Cash Flo Percor and date Nat Income D&A Charge in WC Cash From Operations Cash From Devastments Cash From Investments	Sheet	12.01.0016 84 10 14 12 34 55 FY.2 12.01.2016 41 10	FY4 1231,0017 ## 1131	123131 123131
Percet sees Sales Gross Incurre EEST (Adj.) Earnings Before Tax (Adj.) Not Income (Adj.) Dilated EPS (Adj.) Common Shares Margins & Freditability Radio Percet water Gross Margin R&D % of Sales SG&A % of Sales EBITOA Margin (Adj.) EBIT Margin (Adj.) Not Margin TaxRate	FV-S	3 (8) (8) (8) (8) (8) (8) (8) (8) (8) (8)	FY3 12/31/2015 1 1 2 2 2 2 2 5 2 5 1 1 12/31/2015 102.05 2 12/31/2015 102.05 26.25 402.05	FY2 1231-2916  10  34  41  41  41  10  11  1231-2916  14  1231-2916  41  41  42,0004  47,500  48,0004  49,0004  40,000  40,0004  40,0004	FY-1 12/10/917 0 0 0 0 44 65 68 69 320 22 FY-1 12/10/917 100/94 210/929 210/93 210/93 210/93 210/93 210/93 210/93 210/93 210/93 210/93 210/93 210/93 210/93	FY0 12/21/2010 1 1 1 1 64 65 66 20 22 22 FY0 12/31/2010 12/31/2010 5051 0% 201177% 7/2007% 7/2007% 7/2007%	Aye-CACR  M 2%  M	Consolidated Balance  Annot and date Coash & ST Inventories Inventory Total Assets Core of Liabition Total Shareholders Equity Consolidated Cash Flor Percor and date Not become DAA Chings in WC Cosh From Operations Captal Expenditures Cash From Investments Shares Reportnered	Sheet	12/31/2016 14 15 14 12 34 55 FY-2 12/31/2016 41 13 20 -1 -2 -2	FY4 12312017 III III 12312017 III III III III III III III III III I	123131 123131
Percel sect side  Sales  Gross Incurre  EESTDA (adj)  EEST (adj)  Earnings Before Tax (adj)  Not Income (adj)  Dikmed EPS (adj)  Common Shores  Margines & Fredhobility Reside  Fred ond other  Gross Margin  R&D % of Sales  SG&A % of Sales  EBITDA Margin (adj)  Ret Margin (adj)  Not Margin (adj)	FV-S	1000N 34154 413 413 4157 4 4000N 34154 478154 478154 478154 478154 478154 478154 478154	FY3 12/31/2015 1 1 2 2 2 2 2 5 2 5 1 1 12/31/2015 102.05 2 12/31/2015 102.05 26.25 402.05	FY2 1231-2916  3 34 41 42 41 42 41 42 41 42 41 41 42 41 41 41 41 41 41 41 41 41 41 41 41 41	PY-1 12/01/2017  0 0 0 43 44 66 68 320 22  PY-1 12/01/2017 100/09 2016/09 3046/25 3066/25 3066/25	FY0 12/31/2018 1 1 1 64 65 65 2.02 23 23 FY0 12/31/2018 1000/4 SSE 04 2017/75 2017/75 2017/75 -7/30/75	5yn-CACR 2012% 2012% 2012% 41.2% 40.2% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3% 10.3%	Consolidated Balance  Annor and date Cash & ST Investments Inventory Total Assets Covert Labritos Total Labritos Total Shareholders Equity Consolidated Cash Flo Percor and date Nat Income D&A Charge in WC Cash From Operations Cash From Devastments Cash From Investments	Sheet w Statement	12.01.0016 94 105 14 12 34 55 FY-2 12.01.2016 41 10 20 -1	FY4 1231,0017 ## 1131	12/31/26 12/31/26 12/31/26

# Selecta Biosciences (NASDAQ:SELB)

#### Disclaimer

Please be advised that GeoInvesting<sup>™</sup> is strictly a research and publishing firm, of general and regular circulation, which falls within the publisher's exemption to the definition of an "investment advisor" under Section 202(a)(11)(A) – (E) of the Securities Act (15 U.S.C. 77d(a)(6) (the "Securities Act"). GeoInvesting<sup>™</sup> is not registered as an investment advisor under the Securities Act or under any state laws. None of our trading or investing information, including the Content, GeoInvesting<sup>™</sup> Email, Executive Casts and/or content or communication (collectively, "Information") provides individualized trading or investment advice and should not be construed as such.

Accordingly, please do not attempt to contact GeoInvesting<sup>™</sup>, or SanaCurrents<sup>™</sup>, its members, partners, affiliates, employees, consultants and/or hedge funds managed by partners of GeoInvesting<sup>™</sup> (collectively, the "GeoInvesting<sup>™</sup> Parties") to request personalized investment advice, which they cannot provide. The Information does not reflect the views or opinions of any other publication or newsletter.

We publish Information regarding certain stocks, options, futures, bonds, derivatives, commodities, currencies and/or other securities (collectively, "Securities") that we believe may interest our Users. The Information is provided for information purposes only, and GeoInvesting™ is not engaged in rendering investment advice or providing investment-related recommendations, nor does GeoInvesting™ solicit the purchase of or sale of, or offer any, Securities featured by and/or through the GeoInvesting™ Offerings and nothing we do and no element of the GeoInvesting™ Offerings should be construed as such. Without limiting the foregoing, the Information is not intended to be construed as a recommendation to buy, hold or sell any specific Securities, or otherwise invest in any specific Securities. Trading in Securities involves risk and volatility. Past results are not necessarily indicative of future performance.

The Information represents an expression of our opinions, which we have based upon generally available information, field research, inferences and deductions through our due diligence and analytical processes. Due to the fact that opinions and market conditions change over time, opinions made available by and through the GeoInvesting™ Offerings may differ from time-to-time, and varying opinions may also be included in the GeoInvesting™ Offerings simultaneously. To the best of our ability and belief, all Information is accurate and reliable, and has been obtained from public sources that we believe to be accurate and reliable, and who are not insiders or connected persons of the applicable Securities covered or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer. However, such Information is presented on an "as is," "as available" basis, without warranty of any kind, whether express or implied. GeoInvesting™ makes no representation, express or implied, as to the accuracy, timeliness or completeness of any such Information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and GeoInvesting™ does not undertake to update or supplement any of the Information.

The Information may include, or may be based upon, "Forward-Looking" statements as defined in the Securities Litigation Reform Act of 1995. Forward-Looking statements may convey our expectations or forecasts of future events, and you can identify such statements: (a) because they do not strictly relate to historical or current facts; (b) because they use such words such as "anticipate," "estimate," "expect(s)," "project," "intend," "plan," "believe," "may," "will," "should," "anticipates" or the negative thereof or other similar terms; or (c) because of language used in discussions, broadcasts or trade ideas that involve risks and uncertainties, in connection with a description of potential earnings or financial performance. There exists a variety of risks/uncertainties that may cause actual results to differ from the Forward-Looking statements. We do not assume any obligation to update any Forward-Looking statements whether as a result of new information, future events or otherwise, and such statements are current only as of the date they are made.

You acknowledge and agree that use of GeoInvesting's™ Information is at your own risk. In no event will GeoInvesting™ or any affiliated party be liable for any direct or indirect trading losses caused by any Information featured by and through the GeoInvesting™ Offerings. You agree to do your own research and due diligence before making any investment decision with respect to Securities featured by and through the GeoInvesting™ Offerings. You represent to GeoInvesting™ that you have sufficient investment sophistication to critically assess the Information. If you choose to engage in trading or investing that you do not fully understand, we may not advise you regarding the applicable trade or investment. We also may not directly discuss personal trading or investing ideas with you. The Information made available by and through the GeoInvesting™ Offerings is not a substitute for professional financial advice. You should always check with your professional financial, legal and tax advisors to be sure that any Securities, investments, advice, products and/or services featured by and through the GeoInvesting™ Offerings, as well as any associated risks, are appropriate for you.